TLR7 and chronic myelogenous leukemia, BCR-ABL1 positive: We present a novel hypothesis that administration of the topical TLR-7 agonist imiquimod in the form of AldaraTM may be a useful immunotherapy/adjuvant therapy for CML patients with minimal residual disease.